Search
Search Results
##search.searchResults.foundPlural##
-
-
LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT
1475PDF: 1045HTML: 128 -
PEDIATRIC HODGKIN LYMPHOMA IN LOW- and MIDDLE-INCOME COUNTRIES (LMICs). A NARRATIVE REVIEW Pediatric Hodgkin's lymphoma in low-income countries
1331PDF: 925HTML: 333 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1576PDF: 1118HTML: 259 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2435PDF: 1695HTML: 440 -
DISSEMINATED HISTOPLASMOSIS AS AIDS PRESENTATION. CASE REPORT AND COMPREHENSIVE REVIEW OF CURRENT LITERATURE
3802PDF: 1328HTML: 852Figure 2: 474Figure 1: 3154 -
HIV-ASSOCIATED VENOUS THROMBOEMBOLISM
4524PDF: 1509HTML: 8529 -
FASTING PLASMA GLUCOSE LEVELS WITHIN THE HIGH NORMAL RANGE ARE ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF FUTURE DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β THALASSEMIA: A DECADE-LONG MULTICENTER RETROSPECTIVE ANALYSIS Higher normal fasting plasma glucose and glucose dysregulation in β- thalassemia
745PDF: 283Html: 36 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2256PDF: 2087HTML: 208 -
GROUP-BASED TRAJECTORY MODELING OF PLATELET IN PATIENTS WITH APLASTIC ANEMIA: A STUDY BASED ON THE MIMIC DATABASE
1057PDF: 1046Suppl. Files: 656HTML: 180 -
THE PERFORMANCE OF HOMA 2 COMPARED TO DYNAMIC MARKERS OF INSULIN SECRETION AND SENSITIVITY/RESISTANCE FOR PREDICTING DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: THE EXPERIENCE OF A SINGLE CENTRE HOMA 2 and DYNAMIC MARKERS OF INSULIN SECRETION FOR PREDICTING DYSGLYCEMIA in TDT
157PDF: 139HTML: 41 -
APPROPRIATE DURATION OF INTRAVENOUS TREATMENT OF CANDIDEMIA AND TIMING OF STEP DOWN TO ORAL THERAPY IN NON-NEUTROPENIC PATIENTS
2932PDF: 1134HTML: 453Preferred Reviewers: 221 -
RELIABILITY OF DIFFERENT RBC INDICES AND FORMULAS IN DISCRIMINATING BETWEEN ?-THALASSEMIA MINOR AND OTHER CAUSES OF MICROCYTIC HYPOCHROMIC ANEMIA
2736PDF: 1654HTML: 14662Untitled: 222Untitled: 187 -
TUBERCULOSIS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES
3372PDF: 1277HTML: 8386 -
AN INEXPENSIVE CLINICAL-LABORATORY NOMOGRAM TO PREDICT POST-TREATMENT LUNG DESTRUCTION IN PULMONARY TUBERCULOSIS
642PDF: 319Suppl. Files: 81Html: 70 -
THERAPEUTIC GENE EDITING FOR HEMOGLOBINOPATHIES Gene therapy for Hemoglobinopathies.
2264PDF: 1346Html: 318 -
CD56+/CD38+ Neutrophils: Rapid and Specific Flow Cytometric Signature for Chronic Myeloid Leukemia
254PDF: 289Suppl. Files: 55HTML: 58 -
EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN
3619PDF: 1255HTML: 5089Incidence age-standardized rates for HL across the Mediterranean basin: 224 -
CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma
2422PDF: 1886HTML: 158 -
-
FDG-PET SCAN: A NEW PARADIGM FOR FOLLICULAR LYMPHOMA MANAGEMENT.
3372PDF: 1274HTML: 2363 -
GENETIC HETEROGENEITY OF BETA GLOBIN MUTATIONS AMONG ASIAN-INDIANS AND IMPORTANCE IN GENETIC COUNSELLING AND DIAGNOSIS
1815PDF: 1317HTML: 11568Figure1: 187Figure 2: 191







